Literature DB >> 25470117

Long-Term Assessment of Fibromyalgia in Patients with Culture-Confirmed Lyme Disease.

Gary P Wormser1, Erica Weitzner, Donna McKenna, Robert B Nadelman, Carol Scavarda, Shimon Farber, Priya Prakash, Julia Ash, John Nowakowski.   

Abstract

Background: Fibromyalgia occurs in 2% to 8% of the general population. One of the triggers may be Lyme disease.
Methods: Patients with culture-confirmed Lyme disease who originally presented with erythema migrans have been evaluated annually in a prospective study to determine their long-term outcome. In 2011-2013, subjects were evaluated for fibromyalgia by interview and tender point examination.
Results: 100 subjects were assessed, 52% of whom were male; the mean age was 64.9 years (median 64 years, range 42-86 years). The mean duration of follow-up was 15.4 years (median 16 years, range 11-20 years). At least twenty-four (24%) subjects had experienced a second episode of erythema migrans before the evaluation for fibromyalgia. One patient (1%, 95% C.I.: 0.025 to 5.4%) met criteria for fibromyalgia. The symptoms consistent with fibromyalgia began more than 19 years after Lyme disease was diagnosed. Conclusions: Fibromyalgia was observed in only 1% of 100 patients with culture-confirmed early Lyme disease, a frequency consistent with that found for the general population. This article is protected by copyright. All rights reserved.
Copyright © 2014 American College of Rheumatology.

Entities:  

Year:  2014        PMID: 25470117     DOI: 10.1002/art.38972

Source DB:  PubMed          Journal:  Arthritis Rheumatol        ISSN: 2326-5191            Impact factor:   10.995


  11 in total

Review 1.  Chronic Lyme disease.

Authors:  Paul M Lantos
Journal:  Infect Dis Clin North Am       Date:  2015-06       Impact factor: 5.982

Review 2.  [Etiology and pathophysiology of fibromyalgia syndrome : Updated guidelines 2017, overview of systematic review articles and overview of studies on small fiber neuropathy in FMS subgroups].

Authors:  N Üçeyler; M Burgmer; E Friedel; W Greiner; F Petzke; M Sarholz; M Schiltenwolf; A Winkelmann; C Sommer; W Häuser
Journal:  Schmerz       Date:  2017-06       Impact factor: 1.107

Review 3.  A Review of Post-treatment Lyme Disease Syndrome and Chronic Lyme Disease for the Practicing Immunologist.

Authors:  Katelyn H Wong; Eugene D Shapiro; Gary K Soffer
Journal:  Clin Rev Allergy Immunol       Date:  2021-10-23       Impact factor: 8.667

4.  Long-term Assessment of Post-Treatment Symptoms in Patients With Culture-Confirmed Early Lyme Disease.

Authors:  Erica Weitzner; Donna McKenna; John Nowakowski; Carol Scavarda; Rhea Dornbush; Susan Bittker; Denise Cooper; Robert B Nadelman; Paul Visintainer; Ira Schwartz; Gary P Wormser
Journal:  Clin Infect Dis       Date:  2015-09-18       Impact factor: 9.079

Review 5.  Fibromyalgia: A Critical and Comprehensive Review.

Authors:  Andrea T Borchers; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2015-10       Impact factor: 8.667

6.  Subjective health complaints are not associated with tick bites or antibodies to Borrelia burgdorferi sensu lato in blood donors in western Norway: a cross-sectional study.

Authors:  Reidar Hjetland; Harald Reiso; Camilla Ihlebæk; Roy M Nilsen; Nils Grude; Elling Ulvestad
Journal:  BMC Public Health       Date:  2015-07-14       Impact factor: 3.295

7.  Editorial commentary: life after Lyme disease.

Authors:  Paul G Auwaerter
Journal:  Clin Infect Dis       Date:  2015-04-17       Impact factor: 9.079

Review 8.  Post-treatment Lyme Disease as a Model for Persistent Symptoms in Lyme Disease.

Authors:  Alison W Rebman; John N Aucott
Journal:  Front Med (Lausanne)       Date:  2020-02-25

9.  Controversies in Persistent (Chronic) Lyme Disease.

Authors:  Elizabeth L Maloney
Journal:  J Infus Nurs       Date:  2016 Nov/Dec

Review 10.  Diagnostic confounders of chronic widespread pain: not always fibromyalgia.

Authors:  Winfried Häuser; Serge Perrot; Claudia Sommer; Yoram Shir; Mary-Ann Fitzcharles
Journal:  Pain Rep       Date:  2017-04-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.